CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 17, 2005--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the supplemental Biologics License Application (sBLA) for TYSABRI(R) (natalizumab) for the treatment of multiple sclerosis (MS) has been accepted and designated for Priority Review by the U.S. Food and Drug Administration (FDA).
